April 7, 2014.
Roche announced today that it would buy the US-based molecular diagnostics company IQuum. The Swiss Medtech giant will pay up to $ 450m in the course of the acquisition. The shareholders of IQuum will receive $275 million upfront and up to $175 million when several products related milestones are reached. Roche will integrate IQuum into its Molecular Diagnostics department.
IQuum has developed a new biological sample testing technology called “lab-in-a-tube.” The platform is said to be so simple that even non-specialized clinical personal can quickly learn to use it. By swallowing the company, Roche hopes to set foot in the market of point of care segment of molecular diagnostics. “With IQuum, we further strengthen our molecular diagnostics offerings with cutting-edge technology and products that serve the point of care segment. Patients will benefit from on-the-spot and accurate diagnoses, which will allow healthcare professionals to make rapid, informed treatment decisions in flexible settings,” said Roland Diggelmann, COO of Roche Diagnostics.
– By Thomas Klein, Managing Editor, EMDT
« The Carlyle Group Agrees to Acquire Johnson & Johnson’s Ortho-Clinical Diagnostics for $4.15 Billion Functional brain imaging reliably predicts which vegetative patients have potential to recover consciousness »